| 前收市價 | 128.31 |
| 開市 | 127.80 |
| 買盤 | 0.00 x 1200 |
| 賣出價 | 0.00 x 800 |
| 今日波幅 | 127.50 - 130.13 |
| 52 週波幅 | 75.56 - 138.28 |
| 成交量 | |
| 平均成交量 | 4,844,585 |
| 市值 | 578.54B |
| Beta 值 (5 年，每月) | 0.19 |
| 市盈率 (最近 12 個月) | 48.39 |
| 每股盈利 (最近 12 個月) | 2.67 |
| 業績公佈日 | 2024年5月02日 |
| 遠期股息及收益率 | 1.37 (1.06%) |
| 除息日 | 2024年3月22日 |
| 1 年預測目標價 | 145.06 |
- AASTOCKS
諾和諾德首季度多賺28%並上調全年收入指引 受惠減肥針劑需求升
丹麥生物製藥公司諾和諾德(Novo Nordisk)(NVO.US)首季度純利254億元丹麥克朗(下同)，按年升28%，好過市場預期的237億元，其減肥針劑Wegovy銷售額按年升逾一倍至93.8億元。北美地區整體銷售增長35%，因為期內Wegovy獲美國監管當局批准減輕過胖症帶來的心血管風險。 行政總裁Lars Fruergaard Jorgensen表示，公司正在提升產能，以應對Wegovy需求，季內在美國有約2.7萬名新症人士開始每周接受Wegovy注射。同類產品面對美國競爭對手禮來(LLY.US)旗下Zepbound的競爭，公司表示，Wegovy首季的價格略為下調。 公司將今年全年展望上調，以固定匯率計，估計銷售額增長19%至27%，較之前的預期高出1個百分點。(cy/k)~ 阿思達克財經新聞 網址: www.aastocks.com
- Reuters
UPDATE 5-Novo Nordisk raises outlook fuelled by obesity drug demand
Novo Nordisk raised its 2024 outlook on Thursday and delivered better-than-expected first-quarter profits as the Danish drugmaker races to boost output of its Wegovy weight-loss drug and fend off competition from rival Eli Lilly. Novo is currently the most valuable company in Europe by market capitalisation, worth some 540.4 billion euro ($576.44 billion) before earnings on Thursday, on the back of Wegovy's popularity. Sales growth in the U.S. was positively impacted by a one-off sales adjustment, the company said.
ReutersNovo Nordisk raises 2024 outlook after profit beat fueled by obesity drug demand
LONDON (Reuters) -Novo Nordisk raised its 2024 outlook on Thursday and delivered better-than-expected first-quarter profits as the Danish drugmaker races to boost output of its Wegovy weight-loss drug and fend off competition from rival Eli Lilly. Novo is currently the most valuable company in Europe by market capitalisation, worth some 540.4 billion euro ($576.44 billion) before earnings on Thursday, on the back of Wegovy's popularity. Sales growth in the U.S. was positively impacted by a one-off sales adjustment, the company said.
